Depressants: Benzodiazepines, Barbiturates and GHB

Benzodiazepines (BZDs) are positive allosteric modulators of the gamma-aminobutyric acid type A (GABA-A) receptor, the main inhibitory ligand-gated ion channel in the mammalian central nervous system. The GABA-A receptor is a pentameric complex of alpha, beta, and gamma subunits assembled around a central chloride ion channel. Benzodiazepines bind at the interface between alpha and gamma subunits (specifically the alpha-1, alpha-2, alpha-3, and alpha-5 subunits, but not alpha-4 or alpha-6) at a site distinct from the GABA orthosteric site. When a benzodiazepine occupies this site, it increases the frequency of chloride channel opening in response to GABA without directly opening the channel itself. This is positive allosteric modulation: benzodiazepines require GABA to be present to exert their effect, which is one reason they have a wider therapeutic-to-lethal margin than barbiturates (which can directly open GABA-A channels at high doses, independent of GABA).

The subunit selectivity drives the clinical pharmacological profile. Alpha-1 GABA-A subunits mediate sedation and anterograde amnesia; alpha-2 and alpha-3 mediate anxiolytic and muscle-relaxant effects; alpha-5 mediates hippocampal memory. Classic benzodiazepines such as diazepam are non-selective across alpha-1, -2, -3, and -5 subunits, explaining why they produce sedation alongside anxiolysis. This subunit profile also explains the amnesic effect that makes them relevant to DFSA: activation of alpha-1-containing GABA-A receptors in the hippocampus and prefrontal cortex blocks the consolidation of episodic memory (anterograde amnesia) at clinically relevant plasma concentrations.

Chronic BZD use produces tolerance through receptor downregulation and subunit composition changes. Cross-tolerance between different benzodiazepines, and between benzodiazepines and other GABA-A positive modulators (alcohol, barbiturates, Z-drugs such as zolpidem), is clinically significant. Withdrawal from high-dose chronic BZD use produces a hyperexcitable CNS state (rebound GABAergic inhibition deficiency) that can progress to status epilepticus; BZD withdrawal is one of the few drug-withdrawal syndromes that is life-threatening without medical management.

The analytical challenge of benzodiazepines in forensic casework arises directly from their therapeutic dose range. Unlike cocaine, heroin, or cannabis, where seized material typically contains grams or milligrams of active compound in a larger volume, benzodiazepine tablets are pharmaceutical-grade and dosed at the milligram or even microgram scale.

Diazepam (Valium, Roche; generic), the prototypical long-acting BZD, is formulated at 2, 5, and 10 mg per tablet. Its active metabolite, desmethyldiazepam (nordiazepam), also has anxiolytic activity. Plasma half-life: 20 to 100 hours (parent), producing prolonged effects. Urine detection window: 3 to 7 days for occasional users, up to 30 days for chronic use.

Alprazolam (Xanax, Pfizer; generic) is a short-acting triazolobenzodiazepine dosed at 0.25, 0.5, 1.0, and 2.0 mg. The XR (extended-release) formulation reaches 0.5 to 3 mg. At the 0.25 mg dose, peak plasma levels are approximately 4 to 8 ng/mL after 1 to 2 hours. Urine detection by immunoassay at standard cut-offs (200 ng/mL for BZD immunoassay) is unreliable at these plasma concentrations.

Clonazepam (Klonopin, Roche; generic) is prescribed at 0.5, 1, and 2 mg for epilepsy and panic disorder. Its primary urinary metabolite is 7-aminoclonazepam. Flunitrazepam (Rohypnol, Roche), dosed at 0.5 to 2 mg (since reformulated by Roche in 1997 to include a blue dye that turns drinks blue when dissolved, and to make the tablet crumble rather than dissolve cleanly), produces peak plasma BZD levels after a 1 mg dose of approximately 1.6 ng/mL. Its primary urinary metabolite is 7-aminoflunitrazepam.

Immunoassay-based urine drug screens (EMIT, CLIA, RIA) for benzodiazepines use antibodies raised against diazepam or oxazepam. These antibodies cross-react variably with different BZD compounds, meaning that alprazolam, clonazepam, and especially the designer BZDs (etizolam, flubromazolam) may not be detected at therapeutic or toxic concentrations. LC-MS/MS with a comprehensive BZD inclusion list is the confirmatory standard and sits at the Category A tier of the SWGDRUG identification framework and, for DFSA casework, the primary screening tool. The UNODC recommends LC-MS/MS for DFSA toxicology at detection limits of 0.1 to 1 ng/mL for benzodiazepine metabolites in urine.

Designer benzodiazepines (DBZDs) exploit the same structural modification arms race seen in synthetic cannabinoids and cathinones. By making small modifications to the benzodiazepine scaffold outside the core 1,4-benzodiazepine ring or 1,5-thienodiazepine (etizolam) ring, clandestine chemists produce compounds that are pharmacologically equivalent to scheduled BZDs but fall outside explicit schedule entries.

Etizolam is a thienodiazepine (the 1,4-diazepine ring is fused to a thiophene rather than a benzene ring), which makes it structurally distinct enough from "benzodiazepines" to avoid some broadly written generic scheduling clauses. It is approved and widely prescribed in Japan and South Korea as an anxiolytic. In the US, etizolam is not scheduled federally but is scheduled as a controlled substance in Alabama, Arkansas, Florida, Georgia, Louisiana, Indiana, Mississippi, Texas, and Virginia. The FDA has not approved etizolam for any indication. In the UK, etizolam became a Class C controlled substance under the Misuse of Drugs Act 1971 in 2017 under the designer benzodiazepine regulations (Statutory Instrument 2017 No. 631, The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017, which added etizolam and 15 additional designer benzodiazepines to Class C). In India, the regulatory situation is less clear; etizolam is not explicitly listed in the NDPS Act but is subject to H1-list restrictions under the Drugs and Cosmetics Act requiring a prescription.

Clonazolam (a triazolo analogue of clonazepam) is reported to be extremely potent (active at 0.125 to 0.5 mg), with a prolonged duration and strong amnesic effects. Flubromazolam (a fluorobromo substituted triazolo-BZD) is similarly potent. Bromazolam has appeared in European and North American drug markets since 2020. All three are covered by the UK's generic scheduling SI but remain unscheduled in most US states and in many EU member states (though some have used emergency scheduling procedures).

Forensic detection of DBZDs requires an LC-MS/MS inclusion list that is updated as new compounds appear. Reference standards are available from Cayman Chemical and Cerilliant for the established DBZDs; novel compounds may require NPS reference laboratory analysis. The EMCDDA and the DEA's STRL publish compound alerts that guide forensic laboratory inclusion list updates.

Barbiturates act as positive allosteric modulators of GABA-A receptors, but their mechanism differs critically from benzodiazepines. At therapeutic concentrations, barbiturates increase the duration of chloride channel opening (rather than the frequency as benzodiazepines do). At high concentrations, they can directly activate the GABA-A channel independent of GABA, producing profound CNS and respiratory depression. This direct-activation property is why the therapeutic-to-lethal ratio of barbiturates (approximately 3 to 5:1 for secobarbital) is far narrower than for benzodiazepines, which cannot directly open GABA-A channels.

The barbiturate class is defined by the 5,5-disubstituted barbituric acid (pyrimidine-2,4,6-trione) scaffold. Substituents at the 5-position determine duration of action. Phenobarbital (long-acting, 80 to 120 hours half-life) remains in clinical use as a first-line antiepileptic in low-resource settings and under the WHO Essential Medicines List; it is widely used in Africa, South Asia, and Latin America. Phenobarbital is a Schedule IV drug under the UN Convention on Psychotropic Substances 1971 and is also in the NDPS Act Schedule I (psychotropic substances) in India.

Secobarbital (Seconal, short-acting, half-life 20 to 30 hours) is a Schedule II controlled substance in the US, used historically as a sedative-hypnotic and currently in California, Oregon, Washington, and other states with Death with Dignity Acts as the agent of physician-assisted death for qualifying terminal patients (3 grams in powder form, dissolved in juice). Amobarbital and pentobarbital (Schedule II in the US) are used in lethal-injection protocols in US states. Butalbital remains in combination headache preparations (Fioricet, Schedule III).

In forensic DFSA casework, barbiturates have been largely displaced by benzodiazepines and GHB since the 1980s and 1990s, but pentobarbital and phenobarbital still appear in DFSA toxicology samples, particularly in geographic regions with high phenobarbital prescription prevalence (rural India, Sub-Saharan Africa). GC-MS analysis on a 5% phenylmethyl polysiloxane column resolves phenobarbital (RT approximately 12 to 14 minutes depending on column) from secobarbital, amobarbital, and butalbital. LC-MS/MS provides superior sensitivity and is preferred for blood samples at low concentrations following mixed-drug ingestion.

Gamma-hydroxybutyric acid (GHB, also called sodium oxybate in its pharmaceutical form) is a naturally occurring short-chain fatty acid and GABA metabolite present in the brain and, in trace amounts, in blood and urine of all humans. Endogenous blood GHB concentrations are typically 0.5 to 4 mg/L. Post-mortem redistribution and fermentation by bacteria in non-preserved specimens can raise endogenous GHB to 20 to 50 mg/L, creating a serious interpretive problem for forensic toxicologists. The SWGTOX (Scientific Working Group for Forensic Toxicology) and SOFT (Society of Forensic Toxicologists) have published position papers addressing the endogenous GHB threshold problem.

Exogenous GHB is eliminated rapidly. After ingestion of a pharmacologically active dose (1 to 3 grams), peak blood concentrations of 50 to 150 mg/L are reached within 30 to 60 minutes. Blood half-life is approximately 20 to 30 minutes (the compound is a substrate for succinic semialdehyde dehydrogenase and is rapidly metabolised to succinate, entering the citric acid cycle). Urine GHB excretion is similarly rapid: 90 per cent of the dose is excreted within 6 hours; the window for urine detection extends to approximately 8 to 12 hours post-ingestion at doses of 1 to 3 grams. Hair analysis has been used to extend the detection window for suspected DFSA cases with delayed presentation; GHB incorporation into hair is documented at concentrations above endogenous baseline for up to 3 to 4 months in some studies, but the methodology requires rigorous validation.

Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are prodrugs of GHB. GBL is spontaneously hydrolysed in blood by paraoxonase-1 to GHB within minutes of ingestion; 1,4-BD is oxidised by alcohol dehydrogenase to succinic semialdehyde and thence to GHB. GBL is an industrial chemical solvent (used in paint strippers, wheel cleaners) and was sold openly in the UK before its scheduling under the Misuse of Drugs Act 1971 in 2009 (initially Class C). 1,4-BD was not simultaneously scheduled; it was added to Class C in 2021 under SI 2021/1427. Both GBL and 1,4-BD were subsequently reclassified to Class B by the Misuse of Drugs Act 1971 (Amendment) Order 2022, effective April 2022. Both remain industrial chemicals with legitimate uses, complicating precursor control.

Analytical detection of GHB uses GC-MS after derivatisation (typically ethylation with ethanol and HCl, or conversion to the trimethylsilyl derivative using BSTFA). The GC-MS method resolves GHB from GBL (which may be present if blood was drawn very shortly after ingestion) and from common confounders. LC-MS/MS in negative ion mode (deprotonated [M-H]- at m/z 103 for GHB) provides superior specificity and is the preferred method for low-concentration samples. Quantitative threshold interpretation: blood GHB above 10 mg/L is generally considered above the endogenous range; values above 20 mg/L in preserved specimens are consistent with exogenous exposure, with expert interpretation required for borderline cases.

1. Exhibit triage: identify seizure type
   Is the exhibit a pharmaceutical tablet, a liquid, a powder, or a biological matrix? Tablets: note colour, scoring, imprint codes (cross-reference with Micromedex or national pharmaceutical registry). Liquids suspected of GHB/GBL: secure in glass, refrigerate at 4°C, do not use plastic containers (GBL absorbs to plastics).
2. Presumptive screening (solids)
   Benzodiazepine tablets: Simon-Alder test (furfural-HCl reagent for N-methyl secondary amines, used mainly for MDMA but applicable), or visual microscopy for characteristic crystal habit. GHB powder: no specific presumptive colour test; universal cobalt thiocyanate is negative. Use TLC with vanillin-H2SO4 spray (carbohydrates and hydroxy acids, non-specific).
3. Immunoassay screening (biological matrix)
   Run standard BZD immunoassay screen (EMIT, CLIA) with awareness that alprazolam, clonazepam, and all designer BZDs may produce false negatives. GHB immunoassay (Immunalysis GHB ELISA): screen urine samples collected within 12 hours. Samples beyond 24 hours: hair testing preferred if available.
4. LC-MS/MS confirmation (benzodiazepines)
   C18 column, positive ESI MRM. Diazepam [M+H]+ m/z 285 → 222/193. Alprazolam m/z 309 → 281/205. Flunitrazepam m/z 314 → 268/239. 7-Aminoflunitrazepam m/z 284 → 226/182. Etizolam m/z 343 → 314/286. Flubromazolam m/z 387 → 315. Run certified reference standards for all quantified compounds.
5. GC-MS confirmation (GHB)
   Derivatise urine (100 μL) with ethylation reagent (ethanol/H2SO4, 65°C, 30 min) or BSTFA-TMCS. Inject on DB-5MS column. GHB-TMS: m/z 233 (base peak), 147, 117. Compare endogenous GHB value in matched pre-incident specimen if available. Report with laboratory cut-off (typically 10 mg/L blood, 30 mg/L urine for exogenous interpretation).
6. Result interpretation and reporting
   For DFSA: report all detected BZDs by identity and concentration; apply pharmacokinetic back-calculation if timing data are available. For GHB: compare to established endogenous range (0.5-4 mg/L blood; 1-10 mg/L urine); report any value above cut-off with caveat regarding post-mortem increase, fermentation, and endogenous production if relevant. State detection window limitation explicitly in report.

Drug-facilitated sexual assault (DFSA) refers to sexual assault where the perpetrator administers a substance to incapacitate the victim without consent. In the forensic toxicology literature, DFSA specimens present a consistent cluster of challenges: delayed reporting (mean delay in a 2019 UK Forensic Science International study was 66 hours); alcohol as the co-ingested drug in 70 to 90 per cent of cases, which both potentiates any other depressant and complicates interpretation; and victim recall impairment meaning the reported timeline is unreliable.

The most commonly detected substances in confirmed DFSA cases, in order of frequency across UK, US, and Australian DFSA toxicology studies, are: alcohol (ethanol), cannabis, cocaine, benzodiazepines, and Z-drugs (zolpidem, zopiclone). GHB appears in 1 to 5 per cent of confirmed cases in most study series, though this almost certainly underestimates true prevalence given the short detection window. The widely reported perception that GHB and flunitrazepam are the dominant DFSA drugs is not supported by systematic toxicological evidence; it is largely a media narrative. This matters forensically because a laboratory that screens only for "date rape drugs" using a limited panel will miss the broad spectrum of drugs actually encountered.

UK guidance from the Forensic Science Regulator (FSR 2021 DFSA guidance) and the Royal College of Pathologists Toxicology Guidelines (2022) both recommend: urine and blood samples collected at first clinical contact, hair (10 cm proximal from root) if delayed presentation, and comprehensive LC-MS/MS screening rather than immunoassay alone. The US Crime Victims Fund-funded DFSA toxicology programmes operated through state labs (including the Virginia Department of Forensic Science and the Maryland Office of the Chief Medical Examiner) use similar comprehensive LC-MS/MS panels. In India, DFSA toxicology is under-developed relative to the scale of reported cases; CFSL guidelines for viscera and biological fluid analysis under the NDPS Act framework apply, but no dedicated DFSA toxicology protocol equivalent to the UK FSR guidance existed as of early 2024.